AR115695A1 - Moléculas proteicas multifuncionales que comprenden decorina y uso de estas - Google Patents

Moléculas proteicas multifuncionales que comprenden decorina y uso de estas

Info

Publication number
AR115695A1
AR115695A1 ARP190101887A ARP190101887A AR115695A1 AR 115695 A1 AR115695 A1 AR 115695A1 AR P190101887 A ARP190101887 A AR P190101887A AR P190101887 A ARP190101887 A AR P190101887A AR 115695 A1 AR115695 A1 AR 115695A1
Authority
AR
Argentina
Prior art keywords
protein molecules
multifunctional protein
decorine
molecules including
decorin
Prior art date
Application number
ARP190101887A
Other languages
English (en)
Original Assignee
Catalent Pharma Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Pharma Solutions Llc filed Critical Catalent Pharma Solutions Llc
Publication of AR115695A1 publication Critical patent/AR115695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a moléculas proteicas multifuncionales que comprenden decorina y usos de estas. En particular, la presente se refiere a moléculas proteicas multifuncionales que comprenden decorina y un polipéptido de direccionamiento tal como un anticuerpo y métodos para su producción y usos de estos.
ARP190101887A 2018-07-03 2019-07-03 Moléculas proteicas multifuncionales que comprenden decorina y uso de estas AR115695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862693766P 2018-07-03 2018-07-03

Publications (1)

Publication Number Publication Date
AR115695A1 true AR115695A1 (es) 2021-02-17

Family

ID=69060721

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101887A AR115695A1 (es) 2018-07-03 2019-07-03 Moléculas proteicas multifuncionales que comprenden decorina y uso de estas

Country Status (12)

Country Link
US (3) US11377488B2 (es)
EP (1) EP3817762A4 (es)
KR (1) KR20210040378A (es)
CN (1) CN112638403A (es)
AR (1) AR115695A1 (es)
AU (1) AU2019299110A1 (es)
BR (1) BR112020027026A2 (es)
CA (1) CA3105454A1 (es)
MX (1) MX2021000155A (es)
SG (1) SG11202013217PA (es)
TW (1) TW202012447A (es)
WO (1) WO2020009938A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103590B2 (en) * 2016-09-06 2021-08-31 Cell-Medicine, Inc. Immunostimulant
WO2022028608A1 (zh) * 2020-08-07 2022-02-10 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
CN115927472A (zh) * 2021-07-05 2023-04-07 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
WO2023141856A1 (zh) * 2022-01-27 2023-08-03 岩唐生物科技(杭州)有限责任公司 靶向cd3的多特异性抗体及其应用
CN117679505A (zh) * 2022-09-09 2024-03-12 中山康方生物医药有限公司 药物组合及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US20030224415A1 (en) 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
WO2006038107A2 (en) 2004-08-30 2006-04-13 Mengsu Yang Method for inhibiting fibrogenesis by an rhdecorin-fc fusion protein
CN100376680C (zh) * 2005-11-01 2008-03-26 暨南大学 双重靶效应基因嵌合重组体及其构建方法和应用
EP1948798B1 (en) * 2005-11-18 2015-04-01 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
CN101333252A (zh) * 2008-08-06 2008-12-31 温州医学院 能抑制肿瘤细胞生长和转移的饰胶蛋白及其制备方法和应用
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2349339A4 (en) * 2008-10-16 2015-01-07 Kathleen Cogan Farinas EXTENDED MEDICATION DELIVERY SYSTEM
RU2606016C2 (ru) 2011-01-14 2017-01-10 Редвуд Байосайнс, Инк. Меченые альдегидом полипептиды иммуноглобулина и способы их применения
WO2012125626A2 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof
US9446123B2 (en) * 2012-06-01 2016-09-20 Ibc Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
US10167334B2 (en) * 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
US20190134101A1 (en) * 2016-06-15 2019-05-09 Tissue Regeneration Therapeutics Inc. Genetically modified human umbilical cord perivascular cells for wound healing
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
AU2017371301B9 (en) * 2016-12-09 2023-10-26 Genemedicine Co., Ltd. Anticancer composition comprising recombinant adenovirus expressing degradation factor for extracellular matrix
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
WO2018195386A1 (en) * 2017-04-20 2018-10-25 The University Of Chicago Methods and compositions for treating cancer with ecm-affinity peptides linked to immunotherapeutic antibodies

Also Published As

Publication number Publication date
US20200010539A1 (en) 2020-01-09
US20240150452A1 (en) 2024-05-09
US11377488B2 (en) 2022-07-05
AU2019299110A1 (en) 2021-01-28
KR20210040378A (ko) 2021-04-13
EP3817762A4 (en) 2022-04-13
CN112638403A (zh) 2021-04-09
EP3817762A1 (en) 2021-05-12
JP2021529534A (ja) 2021-11-04
CA3105454A1 (en) 2020-01-09
SG11202013217PA (en) 2021-01-28
BR112020027026A2 (pt) 2021-04-06
MX2021000155A (es) 2021-05-12
US20220275074A1 (en) 2022-09-01
WO2020009938A1 (en) 2020-01-09
US11879009B2 (en) 2024-01-23
TW202012447A (zh) 2020-04-01

Similar Documents

Publication Publication Date Title
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
CL2018003136A1 (es) Proteínas de unión específica y usos de las mismas.
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CL2017003132A1 (es) Moléculas de unión a lag-3 y métodos de uso de las mismas
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CR20190426A (es) Inmunoconjugados
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
UY35286A (es) Construcciones de anticuerpos para CDH19 y CD3
UY36578A (es) Proteínas de unión a tslp
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112016011025A2 (pt) polipeptídeos anticorpo e seus usos
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
BR112017023131A2 (pt) anticorpos anti- fcrn
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas